Back to dashboard
Dr. Jane Smith
Acme Therapeutics
Improve your profile
Tier 2Stronger profile · more relevant invitations · better fit scores. The Profiler agent re-indexes your changes within 60 seconds.
Agents working
Profiler·Re-indexed 2 new PubMed papers into your profile done
Matchmaker·You appeared in 3 new sponsor shortlists running
Negotiator·Drafted reply to Helix Bio invite — awaiting your editapprove
Profile health
78%+12pp
+12 since last monthTrust tier
Tier 2
Verify 1 more credential → Tier 3Capabilities tagged
10
across Skills × Insights × ToolsProfile views · 30d
47
by verified sponsorsMatch appearances · 30d
8
in sponsor shortlistsProfile completeness
78%
The next 12 points unlock priority placement on Tier-2 shortlists.
- Identity & headline92%
→ Add 1-line headline
- Capabilities (4 axes)84%
→ Add 2 more tools
- Verified credentials70%
→ Verify ORCID + 1 trial
- References55%
→ Add 2 references
- Engagement preferences88%
→ Set blackout dates
Capabilities — Skills × Insights × Tools × Experience
Skills
Concrete techniques you can execute on demand.
Phase 2 oncology trial designCMC strategyGLP toxicologyRegulatory CMC submissions
Insights
Pattern recognition across multiple programs / years.
Adaptive Phase 2 design under FDA scrutinyEndpoint selection in solid tumors
Tools
Software, platforms, or wet-lab equipment you're fluent in.
GraphPad PrismSASSpotfireSimCYP
Experience
Roles + years that anchor the rest of your profile.
- Pfizer 2018–2022 (Sr. Director CMC)
- Acme Therapeutics 2022–present (CSO)
Profiler asks · answer to lift completeness
Were you first author on the 2024 Cell paper on PD-L1 trafficking?
ORCID lists the publication but author position is ambiguous. First-author status raises Tier-2 confidence.